399 indexable Biopharmaceuticals companies headquartered in United States, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $1.2B across 12 funded companies.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
avidity biosciences
Avidity Biosciences is a biotechnology company that develops oligonucleotide-based therapies for its patients. |
$142.5M | — | Public | Mar 2024 | 186 | 2013 | — |
| 2 |
rhythm pharmaceuticals
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics |
$84M | — | Public | Apr 2024 | 177 | 2008 | — |
| 3 |
adaptive phage therapeutics
Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. |
$107.9M | — | Acquired | Jun 2023 | 66 | 2016 | — |
| 4 |
annexon biosciences
Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders. |
$256M | — | Public | Jul 2022 | 77 | 2011 | — |
| 5 |
rapt
Rapt offers media monetization solutions, technology, and strategic advisory services for media companies. |
$198.7M | — | Series C | May 2022 | 122 | 2015 | — |
| 6 |
melinta therapeutics
Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to overcome drug-resistant infections. |
$186M | — | Public | Feb 2019 | 162 | 2000 | — |
| 7 |
edge therapeutics
Edge Therapeutics, a biotechnology company, transforms FDA-approved drugs into therapies that address unmet acute neurological conditions. |
$106.1M | — | Public | Aug 2016 | 9 | 2008 | — |
| 8 |
immune design
Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases. |
$101.1M | — | Acquired | May 2014 | 50 | 2008 | — |
| 9 | Neogenix Oncology | $15.8M | — | Acqui-Hired | Oct 2010 | 2 | 2003 | — |
| 10 |
precision biologics
Precision Biologics develops therapeutic and diagnostic products for the early detection and treatment of cancer. |
$14.6M | — | Acquired | Apr 2014 | 7 | 2012 | — |
| 11 |
signature therapeutics, inc.
Signature Therapeutics is focused on creating novel medicines to improve upon the therapeutic utility of existing drugs. |
$10M | — | Acqui-Hired | Dec 2011 | 11 | 2003 | — |
| 12 | MicroBiome Therapeutics | $5.2M | — | Deadpooled | Nov 2017 | 3 | 2009 | — |
| 13 |
respirerx phamaceuticals
A biopharmaceutical company focused on the discovery and development of novel drug therapies for the treatment of sleep apnea. |
— | — | Public | Aug 2020 | 2 | 1987 | — |
| 14 |
oncternal therapeutics
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers. |
— | — | Public | Jul 2020 | 30 | 2013 | — |
| 15 |
celldex therapeutics
Celldex is a clinical stage company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases. |
— | — | Public | Oct 2014 | 148 | 1983 | — |
| 16 | Accelerated Pharma | — | — | Private | — | 6 | 2014 | — |
| 17 |
accurate medical systems
Accurate Medical Systems is a healthcare company that focused on the creation, development, and commercialization of medical technologies. |
— | — | Private | — | 2 | 2017 | — |
| 18 |
acelrx pharmaceuticals
AcelRx Pharmaceuticals focuses on the development and commercialization of therapies for the treatment of pain and other conditions. |
— | — | Public | — | 19 | 2005 | — |
| 19 |
acomhal research
Acomhal Research is a biotech startup company that develops novel treatments targeting cancer cells. |
— | — | Private | — | 2 | 2016 | — |
| 20 |
Actipulse International
Medical company specialized in the clinical research and engineering of Non-Invasive Brain technologies for the treatment of dementia and Parkinson's Disease. |
— | — | — | — | 28 | 2017 | — |
| 21 | Activate Immunotherapy | — | — | Deadpooled | — | 20 | 1997 | — |
| 22 | Acuity Pharmaceuticals | — | — | Acquired | — | 16 | 2002 | — |
| 23 |
acworth pharmaceuticals
Acworth Pharmaceuticals is a biotechnology company specializing in preclinical development for treating cancers. |
— | — | Private | — | 3 | 2016 | — |
| 24 |
Aderans Research Institute
Leaders in the field of Hair Regeneration technology through Cell Therapy applications. |
— | — | — | — | 28 | — | — |
| 25 |
adicyte
AdiCyte offers cryopreservation of adipose tissue and stem cells for patients in cosmetics, regenerative medicine and tissue engineering. |
— | — | Deadpooled | — | 11 | 2011 | — |
| 26 | Adorbs | — | — | Acquired | — | 5 | 2017 | — |
| 27 |
Advanced Diabetic Solutions
Providing innovative,solution based, healthcare products to the market that improve the quality of life for diabetic patients. |
— | — | — | — | 35 | — | — |
| 28 |
aeras
Aeras is a non-profit biotech advancing the development of tuberculosis vaccines for the world. |
— | — | Acquired | — | 73 | 2003 | — |
| 29 |
Aeterna Zentaris
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. |
— | — | — | — | 41 | 1990 | — |
| 30 |
aggamin biologics
Aggamin Biologics is a biotechnology company developing biologic drugs for unmet medical needs. |
— | — | Private | — | 3 | 2010 | — |
| 31 |
akcea therapeutics
Akcea Therapeutics is a development and commercialization company focused on helping patients living with serious and rare diseases. |
— | — | Acquired | — | 294 | 2015 | — |
| 32 | Akyso | — | — | Private | — | 4 | 2014 | — |
| 33 | Alaven Pharmaceutical | — | — | Acquired | — | 180 | 2003 | — |
| 34 | Alcea Therapeutics | — | — | Private | — | 5 | 2020 | — |
| 35 |
alcinous pharmaceuticals
Alcinous Pharmaceuticals designs and develops new molecules that modulate the activity of well-established protein targets. |
— | — | Private | — | 2 | 2016 | — |
| 36 | Alexion Antibody Technologies | — | — | Acquired | — | 23 | 1997 | — |
| 37 | Alfama | — | — | Acquired | — | 15 | 2005 | — |
| 38 | AlkaliDx | — | — | Deadpooled | — | 15 | 2015 | — |
| 39 |
Alkeus Pharmaceuticals
Developing a new treatment for dry age-related macular degeneration and Stargardt disease. |
— | — | — | — | 31 | — | — |
| 40 |
allergease
AllergEase was created by a medical doctor looking for a safe, all-natural treatment to help his family and friends during allergy season. |
— | — | Deadpooled | — | 11 | 2011 | — |
| 41 | Allergy Sciences | — | — | Private | — | 1 | 2011 | — |
| 42 |
allumeros bioscience
Allumeros BioScience develops and researches on therapeutic and diagnostic advancements for treatment of cancer cells. |
— | — | Deadpooled | — | 2 | 2019 | — |
| 43 |
ally therapeutics
Ally Therapeutics solves the immune response barriers for gene therapy. |
— | — | Deadpooled | — | 7 | 2018 | — |
| 44 |
allyx therapeutics
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration. |
— | — | Private | — | 2 | 2018 | — |
| 45 |
alphageneron pharmaceuticals
Alphageneron Pharmaceuticals is a biotechnology company that develops antibody drug conjugates and natural killer cell therapies. |
— | — | Private | — | 4 | 2020 | — |
| 46 |
Alteon (Drug Discovery)
Alteon Inc is a biotechnology company based out of 6 Campus Dr # 2, Parsippany, New Jersey, United States. |
— | — | Acquired | — | 12 | — | — |
| 47 | AltheRx Pharmaceuticals | — | — | Acquired | — | 3 | 2009 | — |
| 48 |
alucent biomedical
Alucent Biomedical is a biomedical company that develops a combination drug-device therapy for the treatment of vascular diseases. |
— | — | Private | — | 20 | — | — |
| 49 |
alxerion biotech
Alxerion Biotech is a colleagues at MIT’s Institute for Medical Engineering and Science. |
— | — | Deadpooled | — | 6 | 2017 | — |
| 50 |
amarillo biosciences
Amarillo Biosciences is a specialty biopharmaceutical company developing a patented formulation of interferon-alpha. |
— | — | Public | — | 43 | 1984 | — |
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is
Operator of a clinical-stage company intended to treat multi-drug resistant pathogenic bacteria. The company provides services by using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of p
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to
Developer of novel small-molecule antibiotics intended to focus on the treatment of resistant infections. The company develops treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections and is focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications, enabling clients to get safe and differentiated antibiotics for
Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adul
Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, imm
Developer of novel therapeutic and diagnostic products. The company focuses on developing novel therapeutic and diagnostic products for the treatment of pancreatic, colon, lung, prostate and various other cancers.
Developer of therapeutic drugs intended to facilitate early detection and treatment of cancer. The company's monoclonal antibody drug candidates and diagnostics products detect and target the tumor without destroying healthy cells, enabling clinicians to treat cancer patients.
Developer of abuse-resistant prescription drugs. The company offers products in the areas of sedative-hypnotic, moderate-to-severe pain, inflammatory pain, opioid-associated side effects, antiemetic, and attention-deficit hyperactivity disorder.
Developer of microbiome modulators intended for metabolic diseases that aim to improve health status by altering microbial populations and their environment in the GI tract. The company's microbiome modulators includes fermentable fiber and polyphenol antioxidants in a patent-pending blendare designed to augment the growth of certain bacterial strains and discourage the growth of others, enabling nurture and nourish
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-17.
